1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Kabi Commits To Biosimilars Development

 
• By Aidan Fry

Fresenius Kabi says a research and development center that it has opened in Switzerland demonstrates its commitment to its biosimilars pipeline.

Kabil
Attendees of the official inauguration of Fresenius Kabi's biosimilars research and development center in Eysins, Switzerland, included the company's CEO, Mats Henriksson (third left) • Source: Fresenius Kabi

Fresenius Kabi said it was committed to developing and marketing biosimilars, especially for autoimmune and oncology indications, as the injectables and infusion specialist inaugurated a biosimilars research and development center that its Fresenius Kabi SwissBioSim unit has built in Eysins, Switzerland. The German company recently took its first commercial step into the biosimilars arena by rolling out its Idacio adalimumab brand in several European countries.

Kabi said the center, in which the firm invested about €15m ($16m), would “intensify biosimilars research and development in the areas of autoimmune diseases and oncology, where the company is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

 
• By Dean Rudge

Teva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.

Fresenius Adds To Denosumab Competitors In Europe

 
• By Dave Wallace

At a busy meeting of the CHMP, the EMA issued positive opinions for Fresenius Kabi’s denosumab rivals to Prolia and Xgeva, another denosumab biosimilar from Sandoz, a Tecfidera hybrid from Neuraxpharm and a Descovy generic from Viatris. Meanwhile, Ascend has withdrawn a teriparatide filing.

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

More from Products

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By Dean Rudge

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

Abiogen And mAbxience Join Forces In Italy

 
• By Dave Wallace

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.